Heinz Sill

Medical University of Graz — Austria

Medicine · Health Sciences

45h-index6.4kcitations344works3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(123), Cancer Genomics and Diagnostics(65), Chronic Myeloid Leukemia Treatments(63), Chronic Lymphocytic Leukemia Research(46), Myeloproliferative Neoplasms: Diagnosis and Treatment(35)

Publications344 total

Lymphotoxin alpha eradicates acute myeloid leukemia and simultaneously promotes healthy hematopoiesis in mice
Science Translational Medicine·2025
Functional drug response profiling predicts clinical outcomes and shows utility for treatment stratification in AML
Blood·2025
Efficacy assessment following shortened venetoclax exposure in AML patients treated with venetoclax plus hypomethylating agents: a real-world, multicentric study
Blood Cancer Journal·2025Open Access
Plasmodium falciparum Kelch13 Variants and Histidine-Rich Protein 2/3 Deletions in Central Ethiopia, 2023
American Journal of Tropical Medicine and Hygiene·2025· 1 citedOpen Access
Engineered cytokine-expressing MSCs support ex vivo culture of human HSPCs and AML cells
Experimental Hematology·2025· 1 cited
Acute myeloid leukemia in the next-generation sequencing era
Wiener klinische Wochenschrift·2024· 3 citedOpen Access
Impact of Mono- and Bi-Allelic <i>TP53</i> Aberrations on Transformation of Human HSPCs
Blood·2024· 1 cited
STAT3 in acute myeloid leukemia facilitates natural killer cell-mediated surveillance
Frontiers in Immunology·2024· 8 citedOpen Access
Multi-drug algorithm to accurately predict best first-line treatments in newly-diagnosed acute myeloid leukemia (AML).
Journal of Clinical Oncology·2024
A novel function of STAT3β in suppressing interferon response improves outcome in acute myeloid leukemia
Cell Death and Disease·2024· 8 citedOpen Access
STAT3β represses interferon signaling in acute myeloid leukemia contributing to favorable disease outcomes
Klinische Pädiatrie·2024
Devimistat plus chemotherapy vs chemotherapy alone for older relapsed or refractory patients with AML: results of the ARMADA trial
Blood Neoplasia·2024· 6 citedOpen Access
Measurable Residual Disease Detection in Acute Myeloid Leukemia: Current Challenges and Future Directions
Biomedicines·2024· 11 citedOpen Access
BRAFV600E promotes DC3/monocyte differentiation in human gene-engineered HSPCs and causes multisystem histiocytosis
Leukemia·2023· 6 citedOpen Access
Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine—A prospective cohort study by the <scp>AGMT</scp>
American Journal of Hematology·2023· 2 citedOpen Access
Figure S5 from Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies
2023Open Access
Data from Increased Expression of miR-23a Mediates a Loss of Expression in the RAF Kinase Inhibitor Protein RKIP
2023Open Access
Figure S1 from Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies
2023Open Access
Supplementary Figure Legends from Increased Expression of miR-23a Mediates a Loss of Expression in the RAF Kinase Inhibitor Protein RKIP
2023Open Access
Figure S1 from Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies
2023Open Access
page 1 of 18Next →

Frequent Co-authors

Armin Zebisch(17), Albert Wölfler(14), Werner Linkesch(13), Christine Beham‐Schmid(9), Ellen Heitzer(7), Peter Ulz(7), Peter Neumeister(7), Wolfgang R. Sperr(7), Jochen B. Geigl(6), Eduard Schulz(6), K. Lind(6), Gerald Höefler(6), Martin Pichler(5), Michael R. Speicher(5), Holger W. Auner(5), Franz Quehenberger(5), Robert Krause(5), Karl Kashofer(5), Peter Valent(5), Ute Apfelbeck(4)